Trials / Recruiting
RecruitingNCT07392736
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 228 (estimated)
- Sponsor
- Advenchen Laboratories, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL8326 tablets | Tablet: 10mg/tablet; administered orally once daily |
| DRUG | Toripalimab | 240mg Injection solution：21-Day cycles |
Timeline
- Start date
- 2021-10-26
- Primary completion
- 2029-11-07
- Completion
- 2029-11-07
- First posted
- 2026-02-06
- Last updated
- 2026-02-06
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07392736. Inclusion in this directory is not an endorsement.